
EquitySector - HealthcareVery High Risk
Direct
NAV (18-May-26)
Returns (Since Inception)
Fund Size
₹2,939 Cr
Expense Ratio
0.45%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.45%
+12.02% (Cat Avg.)
3 Years
+28.85%
+25.62% (Cat Avg.)
5 Years
+16.77%
+14.49% (Cat Avg.)
Since Inception
+21.71%
— (Cat Avg.)
| Equity | ₹2,937.91 Cr | 99.96% |
| Others | ₹1.32 Cr | 0.04% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹345.77 Cr | 11.76% |
| Divi's Laboratories Ltd | Equity | ₹242.01 Cr | 8.23% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹209.2 Cr | 7.12% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹187.86 Cr | 6.39% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹174.34 Cr | 5.93% |
| Lupin Ltd | Equity | ₹134.32 Cr | 4.57% |
| Dr Reddy's Laboratories Ltd | Equity | ₹130.59 Cr | 4.44% |
| Aurobindo Pharma Ltd | Equity | ₹123.99 Cr | 4.22% |
| Fortis Healthcare Ltd | Equity | ₹119.35 Cr | 4.06% |
| Laurus Labs Ltd | Equity | ₹108.75 Cr | 3.70% |
| Alkem Laboratories Ltd | Equity | ₹103.08 Cr | 3.51% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹96.35 Cr | 3.28% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹94.95 Cr | 3.23% |
| OneSource Specialty Pharma Ltd | Equity | ₹94.64 Cr | 3.22% |
| Cipla Ltd | Equity | ₹92.8 Cr | 3.16% |
| Sai Life Sciences Ltd | Equity | ₹91.9 Cr | 3.13% |
| Ipca Laboratories Ltd | Equity | ₹89.01 Cr | 3.03% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹86.98 Cr | 2.96% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹71.4 Cr | 2.43% |
| Dr. Lal PathLabs Ltd | Equity | ₹58.58 Cr | 1.99% |
| Gland Pharma Ltd | Equity | ₹53.53 Cr | 1.82% |
| Mankind Pharma Ltd | Equity | ₹51.55 Cr | 1.75% |
| Narayana Hrudayalaya Ltd | Equity | ₹38.46 Cr | 1.31% |
| Anthem Biosciences Ltd | Equity | ₹37.09 Cr | 1.26% |
| Biocon Ltd | Equity | ₹34.88 Cr | 1.19% |
| Neogen Chemicals Ltd | Equity | ₹16.86 Cr | 0.57% |
| Deepak Nitrite Ltd | Equity | ₹15.9 Cr | 0.54% |
| Sudeep Pharma Ltd | Equity | ₹14.19 Cr | 0.48% |
| Torrent Pharmaceuticals Ltd | Equity | ₹13.47 Cr | 0.46% |
| Treps | Cash - Repurchase Agreement | ₹4.55 Cr | 0.15% |
| Net Receivables / (Payables) | Cash | ₹-3.47 Cr | 0.12% |
| Wockhardt Ltd | Equity | ₹3.04 Cr | 0.10% |
| Rubicon Research Ltd | Equity | ₹2.98 Cr | 0.10% |
| Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.24 Cr | 0.01% |
| Syngene International Ltd | Equity | ₹0.1 Cr | 0.00% |
Large Cap Stocks
36.42%
Mid Cap Stocks
35.71%
Small Cap Stocks
27.83%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹2,905.15 Cr | 98.84% |
| Basic Materials | ₹32.76 Cr | 1.11% |
Standard Deviation
This fund
16.84%
Cat. avg.
16.62%
Lower the better
Sharpe Ratio
This fund
1.08
Cat. avg.
0.99
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.77
Higher the better

Since July 2018
Since April 2025
ISIN INF769K01ED6 | Expense Ratio 0.45% | Exit Load 1.00% | Fund Size ₹2,939 Cr | Age 7 years 11 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,06,170 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments